等待开盘 09-04 09:30:00 美东时间
-0.260
-0.49%
Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.
09-02 22:38
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.
08-22 23:21
- DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control -- Offers longest dosing option for HAE, with dosing every 4 or 8 weeks -- Compelling profile supported by
08-21 23:46
JP Morgan analyst Rohin Patel downgrades Haemonetics (NYSE:HAE) from Overweight to Neutral and lowers the price target from $85 to $62.
08-08 18:37
今日重点评级关注:HC Wainwright & Co.:维持FibroGen"买入"评级,目标价从10美元升至43美元;摩根大通:维持Cogent Biosciences"超配"评级,目标价从29美元升至30美元
08-08 09:34
Haemonetics (NYSE:HAE) affirms FY2026 Adj EPS guidance from $4.70-$5.00 to $4.70-$5.00 vs $4.87 analyst estimate..
08-07 18:05
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.02 by 7.95 percent. This is a 7.84 percent increase over earnings of $1.02 per share from the same
08-07 18:02
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Dentsply Sirona (NASDAQ:XRAY) is gearing up to announce its quarterly earnings ...
08-07 01:06
Haemonetics's (NYSE:HAE) short percent of float has fallen 4.44% since its last...
08-07 01:00